Brief: Sight Sciences Receives FDA 510(K) Clearance Of The Tearcare System For Treatment Of Meibomian Gland Dysfunction (Mgd), The Leading Cause Of Dry Eye Disease
22/12/2021 13:13
Dec 22 (Reuters) - Sight Sciences Inc SGHT.O :
* SIGHT SCIENCES RECEIVES FDA 510(K) CLEARANCE OF THE
TEARCARE®
SYSTEM FOR TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION (MGD), THE
LEADING CAUSE OF DRY EYE DISEASE
Source text for Eikon: ID:nGNX90ys6n
Further company coverage: SGHT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sight Sciences
See all newsSight Sciences raises FY 2026 revenue outlook
Brief: Sight Sciences Q1 Revenue USD 19.7 Million Vs. IBES Estimate USD 18.5 Million
Brief: Sight Sciences U.S. District Court Issued Order On Post-Trial Motions In Patent Infringement Case Against Alcon Originally Filed On Sep 16, 2021
Sight Sciences Q4 revenue rises 7%
Brief: Sight Sciences Announces Preliminary, Unaudited Fourth Quarter And Full Year 2025 Financial Highlights